SELLAS Life Sciences Group Inc Stock
Heavy losses for SELLAS Life Sciences Group Inc today as the stock fell by -€0.740 (-7.120%).
With 2 Sell predictions and 0 Buy predictions the community sentiment towards the SELLAS Life Sciences Group Inc stock is not clear.
The target price of 1 € compared with the current price of 9.66 € for the stock indicates a negative potential of -89.65%.
For the coming years our community has positive and negative things to say abot the SELLAS Life Sciences Group Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Innovation" there were negative voices in the community.
SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Pros and Cons of SELLAS Life Sciences Group Inc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of SELLAS Life Sciences Group Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | -7.120% | 19.816% | -13.693% | 663.583% | 266.843% | 640.741% | 39.037% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | -1.905% | 9.574% | 9.574% | 14.955% | 23.798% | -44.624% |
| Eledon Pharmaceuticals Inc. | 6.850% | 0.000% | -13.174% | 26.087% | 126.563% | 156.637% | -46.296% |
| Grifols S.A. ADR | 0.750% | -3.597% | 8.943% | -25.140% | -11.842% | -25.967% | -46.943% |